Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Rolando Pajon
Moderna, Inc.
United States
Contact
Moderna, Inc.
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
2
DOWNLOADS
207
TOTAL CITATIONS
0
Feedback
Scholarly Papers (2)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial
Number of pages: 40
Posted: 29 Dec 2021
Hana M. El Sahly
,
Lindsey Baden
,
Brandon Essink
,
David C. Montefiori
,
Adrian McDermont
,
Richard Rupp
,
Michael Lewis
,
Shobha Swaminathan
,
Carl Griffin
,
Veronica Fragoso
,
Vicki E. Miller
,
Bethany Girard
,
Yamuna D. Paila
,
Weiping Deng
,
Joanne E. Tomassini
,
Robert Paris
,
Florian Schodel
,
Rituparna Das
,
Alison August
,
Brett Leav
,
Jacqueline M. Miller
,
Honghong Zhou
, Rolando Pajon and
COVE Study Group
Baylor College of Medicine, Harvard University - Brigham and Women’s Hospital, Meridian Clinical Research, Duke University - Duke Human Vaccine Institute, Government of the United States of America - Vaccine Research Center, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, Government of the United States of America - VA Greater Los Angeles Healthcare System (GLA), Rutgers, The State University of New Jersey - New Jersey Medical School, Lynn Health Science Institute (Lynn Institute), DM Clinical Research - Texas Center for Drug Development (TCDD), DM Clinical Research, Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc. and Independent
Downloads
126
(572,948)
View PDF
Download
Abstract:
mRNA-1273, immunogenicity, antibodies, SARS-CoV-2, vaccine
2.
SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines
Number of pages: 45
Posted: 01 Feb 2021
Xiaoying Shen
,
Haili Tang
,
Charlene McDanal
,
Kshitij Wagh
,
Will M. Fischer
,
James Theiler
,
Hyejin Yoon
,
Dapeng Li
,
Barton F. Haynes
,
Kevin O. Saunders
,
S. Gnanakaran
,
Nicolas W. Hengartner
, Rolando Pajon,
Gale Smith
,
Filip Dubovsky
,
Gregory M. Glenn
,
Bette T. Korber
and
David C. Montefiori
Duke University - Duke Human Vaccine Institute, Duke University - Department of Surgery, Duke University - Department of Surgery, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Moderna, Inc., Novavax, Inc., Novavax, Inc., Novavax, Inc., Los Alamos National Laboratory - Theoretical Biology and Biophysics and Duke University - Duke Human Vaccine Institute
Downloads
81
(796,622)
View PDF
Download
Abstract:
Feedback